menu
    • menu
    [{"orgOrder":0,"company":"ImaginAb","sponsor":"ImaginAb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"67Cu-SARTATE","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ ImaginAb","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ ImaginAb"},{"orgOrder":0,"company":"ImaginAb","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ Roche"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Parthenon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"PRTH-101","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ Parthenon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"ImaginAb \/ Parthenon Therapeutics"},{"orgOrder":0,"company":"ImaginAb","sponsor":"DynamiCure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DCBY02","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ DynamiCure","highestDevelopmentStatusID":"6","companyTruncated":"ImaginAb \/ DynamiCure"},{"orgOrder":0,"company":"ImaginAb","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ TriSalus Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"ImaginAb \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"89Zr-crefmirlimab","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ Leucid Bio","highestDevelopmentStatusID":"4","companyTruncated":"ImaginAb \/ Leucid Bio"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IAB56","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImaginAb \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by ImaginAb

    Menu

    ImaginAb

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAB56

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical Development

                            Details : IAB56 is a minibody, RPT agent is designed to target integrin avb6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies.

                            Brand Name : IAB56

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 18, 2023

                            Lead Product(s) : IAB56

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LEU011,89Zr-crefmirlimab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Leucid Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio

                            Details : Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET tracer, 89Zr crefmirlimab berdoxam, to Leucid for use in its basket study in solid tumors, with LEU011 targeting NKG2DL, Autolog...

                            Brand Name : LEU011

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 12, 2023

                            Lead Product(s) : LEU011,89Zr-crefmirlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Leucid Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SD-101,Pembrolizumab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : TriSalus Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

                            Details : Under the agreement, ImaginAb will license and supply clinical doses of investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery method for intravascular delivery of its investigational...

                            Brand Name : SD-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 22, 2022

                            Lead Product(s) : SD-101,Pembrolizumab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : TriSalus Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DCBY02

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : DynamiCure

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology

                            Details : Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPET, DCBY02 to DynamiCure Biotechnology for use in its clinical trial.

                            Brand Name : DCBY02

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 15, 2022

                            Lead Product(s) : DCBY02

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : DynamiCure

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRTH-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Parthenon Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer ...

                            Details : Parthenon will use ImaginAb’s CD8 ImmunoPET imaging agent 89Zr crefmirlimab berdoxam in its Phase 1 trial evaluating its lead compound, PRTH-101, which is expected to begin in 2023.

                            Brand Name : PRTH-101

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 10, 2022

                            Lead Product(s) : PRTH-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Parthenon Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ImaginAb and Roche Have Entered a Clinical Trial Supply Agreement for Provision of Atezolizumab (Tecentriq®)1...

                            Details : ImaginAb announced the launch of its Phase IIb “iPREDICT” trial in January this year, as it continues to develop clinical data to support marketing approval of its investigational CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam).

                            Brand Name : Tecentriq

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 08, 2022

                            Lead Product(s) : Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 67Cu-SARTATE

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : ImaginAb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets

                            Details : Clarity and ImaginAb will combine their proprietary technologies to develop novel minibody and cys-diabody radiopharmaceutical products using Clarity's copper chelators to fully exploit the benefits of the theranostic pairing of copper-64 or copper-67.

                            Brand Name : Sartate

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 21, 2020

                            Lead Product(s) : 67Cu-SARTATE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : ImaginAb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth